NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$32.09
−0.99%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$33.17
From 52W high−25.09%
Volume1.39M
Market cap$642.17M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$33.17
From 52W high
−25.09%
Volume
1.39M
Market cap
$642.17M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.0x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
−0.99%
YTD Return
+54.52%
SummaryUpdated Jun 1, 2026
Neurogene Inc. (NASDAQ:NGNE) is a clinical-stage biotechnology company founded in 2014 and headquartered in New York, New York. The company specializes in developing gene therapies for rare neurological diseases, focusing on conditions that primarily affect children and have limited or no treatment options. Since its initial public offering in 2014, Neurogene has been advancing its pipeline of investigational treatments through clinical trials, with its lead programs targeting Rett syndrome and Batten disease.
Similar companies
Latest newsMore news →
Neurogene Inc. granted non-qualified stock options to purchase 38,330 shares of common stock to two new employees as inducement grants on September 1, 2026.16d agoNeurogene Inc. completed an oversubscribed financing raising approximately $144 million in gross proceeds, with net proceeds of approximately $134.8 million from a July 2026 public offering.41d ago